| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 07/24/2003 | WO2002053770A3 Method for the prediction of the risk potential for cancerous diseases and inflammatory intestinal diseases and corresponding tests |
| 07/24/2003 | WO2002049575A3 Method and composition for the treatment of diabetic neuropathy |
| 07/24/2003 | WO2002036100A9 Controlled release metformin compositions |
| 07/24/2003 | US20030139616 Alcohol extraction to remove intracellular free cholesterol |
| 07/24/2003 | US20030139607 Antiarrhythmic agents, treating cardiovascular disorders, infarct prophylaxis, angina pectoris, shock, stroke, transplant organ surgery |
| 07/24/2003 | US20030139604 Solid state nuclear magnetic resonance spectrum, phase shifting, infrared spectrum analysis; treating prophylaxis of diabetes mellitus |
| 07/24/2003 | US20030139590 Comprises nucleotide sequences coding orphan receptor 25 for detecting modulators of platelet activating factor (PAF) activity; antiinflammatory agents; gene/translation inhibition; drug screening |
| 07/24/2003 | US20030139585 Oligonucleotide derivatives which are at least partly double-stranded and which have a 2'5'-linked oligonucleotide residue on at least one 3' end; use in formulating pharmaceutical for tumor therapy, infectious diseases |
| 07/24/2003 | US20030139475 Novel tricyclic compounds and drug compositions containing same |
| 07/24/2003 | US20030139467 Diuretics containing y-tocotrienol |
| 07/24/2003 | US20030139462 Antiinflammatory agents; autoimmune disease; antiarthritic agents |
| 07/24/2003 | US20030139461 Antidiabetic formulation and method |
| 07/24/2003 | US20030139452 Pyrazole-derived kinase inhibitors and uses thereof |
| 07/24/2003 | US20030139435 N-heterocyclic inhibitors of TNF-alpha expression |
| 07/24/2003 | US20030139434 Combinations comprising dipeptidylpeptidase-iv inhibitor |
| 07/24/2003 | US20030139428 Purine derivatives for treatment of gastrointestinal disorders, immunological disorders, neurological disorders |
| 07/24/2003 | US20030139423 Central nervous system disorders; psychological disorders |
| 07/24/2003 | US20030139417 Cyclopropane CGRP antagonists, medicaments containing these compounds, and method for the production thereof |
| 07/24/2003 | US20030139413 Novel 1,3-dihydro-2h-indol-2-one derivatives, preparation method and pharmaceutical composition containing them |
| 07/24/2003 | US20030139407 Efficient synthesis of 5-heteroatom-containing -pyrazoles |
| 07/24/2003 | US20030139402 Antiinflammatory agents; Alzheimer's disease; cardiovascular disorders |
| 07/24/2003 | US20030139398 Quinazoline and quinazoline-like compounds for the treatment of integrin-mediated disorders |
| 07/24/2003 | US20030139394 Dibenzodiazepine derivatives, their preparation and use |
| 07/24/2003 | US20030139384 Transdermal supplying testosterone |
| 07/24/2003 | US20030139378 Liquid bisphosphonate formulations for bone disorders |
| 07/24/2003 | US20030139376 Lipoxin A4 analogs |
| 07/24/2003 | US20030139350 Use of glycosides of mono- and diacylglycerol as anti-inflammatory agents |
| 07/24/2003 | US20030138951 Conversion of liver stem and progenitor cells to pancreatic functional cells |
| 07/24/2003 | US20030138931 Hydrolase polypeptide for dephosphorylating mitogen activated kinases (MAP-kinase); antiapoptosis; antiproliferative agents |
| 07/24/2003 | US20030138839 Polypeptide comprising ubiquitination regulating domain; antiproliferative agents; neuroprotectants; cancer diagnosis |
| 07/24/2003 | US20030138832 Modulating insulin receptor signaling through targeting FACL |
| 07/24/2003 | US20030138820 Sugar transport protein for use in diagnosis and treatment of diabetes, hypertriglyceridemia and hyperinsulinemia |
| 07/24/2003 | US20030138803 Identification and use of molecules implicated in pain |
| 07/24/2003 | US20030138772 Polymerase chain reactions to screen and isolate parvovirus DNA obtained from tissue and/or cells without coinfection by helper viruses; gene therapy |
| 07/24/2003 | US20030138476 Use of glutamate and/or a glutamate precursor for the preparation of a nutritional or pharmaceutical preparation for the treatment or prevention of hyperpermeability or undesired permeability of the intestinal wall |
| 07/24/2003 | US20030138422 Antibodies against growth and differentiation factor-8 (GDF-8), also known as myostatin, including fragments; muscle and bone degenerative disorders; muscular dystropy/atrophy; antidiabetic agents; congestive obstructive pulmonary disease |
| 07/24/2003 | US20030138396 Administering a lipase inhibitor and a pharmaceutically acceptable bile acid sequestrant; anticholesterol agents |
| 07/24/2003 | CA2841097A1 Albumin fusion proteins |
| 07/24/2003 | CA2680946A1 Pim-3 kinase as a target for type 2 diabetes mellitus |
| 07/24/2003 | CA2477348A1 Nucleic acids encoding a g-protein coupled receptor involved in islet cell signaling |
| 07/24/2003 | CA2474014A1 Pharmaceutical composition comprising 2,2-dichloro-12-(4-chlorophenyl)-dodecanoic acid |
| 07/24/2003 | CA2473893A1 Stable salts of o-acetylsalicylic acid with basic amino acids ii |
| 07/24/2003 | CA2473236A1 Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1h-benzoimidazole analogues |
| 07/24/2003 | CA2473207A1 Halogenobenzylaminopropionic acid derivatives |
| 07/24/2003 | CA2472746A1 Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof |
| 07/24/2003 | CA2472470A1 Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues |
| 07/24/2003 | CA2472419A1 Coumarin derivatives, process for their production and use thereof |
| 07/24/2003 | CA2472223A1 Derivatives of alpha-phenylthiocarboxylic and alpha-phenyloxy-carboxylic acids useful for the treatment of diseases responding to pparalpha activation |
| 07/24/2003 | CA2472209A1 Pheny(alkyl)carboxylic acid derivatives and dionic phenylalkylheterocyclic derivatives and their use as medicines with serum glucose and/or serum lipid lowering activity |
| 07/24/2003 | CA2472204A1 N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases |
| 07/24/2003 | CA2472168A1 Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor |
| 07/24/2003 | CA2472016A1 Method and device for identifying substances capable of modulating adipicyte differentiation |
| 07/24/2003 | CA2471620A1 Pyrrolidone carboxamides |
| 07/24/2003 | CA2471480A1 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 07/24/2003 | CA2471363A1 Albumin fusion proteins |
| 07/24/2003 | CA2471311A1 Aromatic thioether liver x-receptor modulators |
| 07/24/2003 | CA2470400A1 Cultured and encapsulated pancreatic stem cells |
| 07/24/2003 | CA2470359A1 Assay for the detection of factors that modulate the expression of ingap |
| 07/24/2003 | CA2469800A1 Methods for the induction of professional and cytokine-producing regulatory cells |
| 07/24/2003 | CA2469435A1 Modulators of lxr |
| 07/23/2003 | EP1329508A1 Novel g protein-coupled receptor protein and dna thereof |
| 07/23/2003 | EP1329458A2 Peptides that lower blood glucose levels |
| 07/23/2003 | EP1329456A1 Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same |
| 07/23/2003 | EP1329217A1 Solid preparations |
| 07/23/2003 | EP1328653A2 Highly expressible genes |
| 07/23/2003 | EP1328624A2 B7-like molecules and uses thereof |
| 07/23/2003 | EP1328548A2 Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design |
| 07/23/2003 | EP1328539A1 Vegf peptides and their use for inhibiting angiogenesis |
| 07/23/2003 | EP1328525A2 2,3,4,5-tetrahydro-1h-[1,4]diazepino[1,7-a]indole compounds |
| 07/23/2003 | EP1328522A2 Estrogen receptor modulators |
| 07/23/2003 | EP1328521A2 A crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride |
| 07/23/2003 | EP1328519A2 Orally active salts with tyrosine kinase activity |
| 07/23/2003 | EP1328515A1 Indoline derivatives and their use as 5-ht2 receptor ligands |
| 07/23/2003 | EP1328514A1 Amide derivatives as nmda receptor antagonists |
| 07/23/2003 | EP1328512A2 Cyclylamine sulfonamides as beta-3 adrenergic receptor agonists |
| 07/23/2003 | EP1328508A2 Propionic acid derivatives with ppar-alpha activating properties |
| 07/23/2003 | EP1328319A1 7-amino-2-alkylthiopteridin-4-yl-amines for the treatment of chemokine-related diseases |
| 07/23/2003 | EP1328286A1 Bone health compositions derived from milk |
| 07/23/2003 | EP1328282A1 Efficient method for producing compositions enriched in anthocyanins |
| 07/23/2003 | EP1328280A1 New composition and method for the treatment of dysglucaemia |
| 07/23/2003 | EP1328269A2 Association of the cb1 receptor antagonist and a sibutramin for treating obesity |
| 07/23/2003 | EP1328266A1 Combination of fenofibrate and coenzyme q10 for the treatment of endothelial dysfunction |
| 07/23/2003 | EP1328265A2 Novel uses for thyroid hormones or thyroid hormone-like agonist compounds for treating dermis conditions |
| 07/23/2003 | EP1328261A2 Treatment of neurodegenerative disease |
| 07/23/2003 | EP1328245A1 Dental care compositions |
| 07/23/2003 | EP1254134B1 1,3-dihydro-2h-indol-2-one derivatives,and their use as ligands for v1b or v1b and v1a arginine-vasopressin-receptors |
| 07/23/2003 | EP1228073B1 Imidazole compounds used as phosphodiesterase vii inhibitors |
| 07/23/2003 | EP1204654B1 Benzofurylpiperazines: 5-ht2c serotonin receptor agonists |
| 07/23/2003 | EP1148876A4 Calcilytic compounds |
| 07/23/2003 | EP1107741B1 Orally administered controlled drug delivery system providing temporal and spatial control |
| 07/23/2003 | EP1075259B1 Novel fatty analogues for the treatment of diabetes |
| 07/23/2003 | EP1032575B1 2,3-diaryl-pyrazolo(1,5-b)pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (cox-2) inhibitors |
| 07/23/2003 | EP1007024B1 Delayed-release dosage forms of sertraline |
| 07/23/2003 | EP0888278B1 Antidiabetic agents |
| 07/23/2003 | EP0808163B1 Use of thiazolium compounds for preventing and reversing the formation of advanced glycosylation endproducts |
| 07/23/2003 | EP0695183B1 Use of thiazolidinediones for the treatment of atherosclerosis and eating disorders |
| 07/23/2003 | CN1432020A 嘌呤衍生物 Purine derivatives |
| 07/23/2003 | CN1432011A Benzoamide piperidine compounds as substance P antagonists |
| 07/23/2003 | CN1432007A Inhibitors of alpha L beta 2 mediated cell adhesion |
| 07/23/2003 | CN1432004A Alkynyl phenyl heteroaromatic glucokinase activators |